Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years.
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
31 03 2021
31 03 2021
Historique:
received:
09
12
2020
accepted:
16
03
2021
entrez:
1
4
2021
pubmed:
2
4
2021
medline:
29
6
2021
Statut:
epublish
Résumé
Spinal muscular atrophy (SMA) is the most common neurodegenerative disease in childhood. Since motor neuron injury is usually not reversible, early diagnosis and treatment are essential to prevent major disability. Our objective was to assess the impact of genetic newborn screening for SMA on outcome. We provided clinical data from 43 SMA patients, identified via polymerase chain reaction of the SMN1 gene from dried blood spots between January 2018 and January 2020 in Germany. Follow-up included neurophysiological examinations and standardized physiotherapeutic testing. Detection of SMA with newborn screening was consistent with known incidence in Germany. Birth prevalence was 1:6910; 39.5% had 2 SMN2 copies, 23% had 3 SMN2 copies, 32.5% had 4 copies, and 4.5% had 5 copies of the SMN2 gene. Treatment with SMA-specific medication could be started at the age of 14-39 days in 21 patients. Pre-symptomatically treated patients remained throughout asymptomatic within the observation period. 47% of patients with 2 SMN2 copies showed early, presumably intrauterine onset of disease. These patients reached motor milestones with delay; none of them developed respiratory symptoms. Untreated children with 2 SMN2 copies died. Untreated children with 3 SMN2 copies developed proximal weakness in their first year. In patients with ≥ 4 SMN2 copies, a follow-up strategy of "watchful waiting" was applied despite the fact that one of them was treated from the age of 6 months. Two infant siblings with 4 SMN2 copies were identified with a missed diagnosis of SMA type 3. Identification of newborns with infantile SMA and prompt SMA-specific treatment substantially improves neurodevelopmental outcome, and we recommend implementation in the public newborn screening in countries where therapy is available. Electrophysiology is a relevant parameter to support the urgency of therapy. There has to be a short time interval between a positive screening result and referral to a therapy-ready specialized treatment center.
Sections du résumé
BACKGROUND
Spinal muscular atrophy (SMA) is the most common neurodegenerative disease in childhood. Since motor neuron injury is usually not reversible, early diagnosis and treatment are essential to prevent major disability. Our objective was to assess the impact of genetic newborn screening for SMA on outcome.
METHODS
We provided clinical data from 43 SMA patients, identified via polymerase chain reaction of the SMN1 gene from dried blood spots between January 2018 and January 2020 in Germany. Follow-up included neurophysiological examinations and standardized physiotherapeutic testing.
RESULTS
Detection of SMA with newborn screening was consistent with known incidence in Germany. Birth prevalence was 1:6910; 39.5% had 2 SMN2 copies, 23% had 3 SMN2 copies, 32.5% had 4 copies, and 4.5% had 5 copies of the SMN2 gene. Treatment with SMA-specific medication could be started at the age of 14-39 days in 21 patients. Pre-symptomatically treated patients remained throughout asymptomatic within the observation period. 47% of patients with 2 SMN2 copies showed early, presumably intrauterine onset of disease. These patients reached motor milestones with delay; none of them developed respiratory symptoms. Untreated children with 2 SMN2 copies died. Untreated children with 3 SMN2 copies developed proximal weakness in their first year. In patients with ≥ 4 SMN2 copies, a follow-up strategy of "watchful waiting" was applied despite the fact that one of them was treated from the age of 6 months. Two infant siblings with 4 SMN2 copies were identified with a missed diagnosis of SMA type 3.
CONCLUSION
Identification of newborns with infantile SMA and prompt SMA-specific treatment substantially improves neurodevelopmental outcome, and we recommend implementation in the public newborn screening in countries where therapy is available. Electrophysiology is a relevant parameter to support the urgency of therapy. There has to be a short time interval between a positive screening result and referral to a therapy-ready specialized treatment center.
Identifiants
pubmed: 33789695
doi: 10.1186/s13023-021-01783-8
pii: 10.1186/s13023-021-01783-8
pmc: PMC8011100
doi:
Substances chimiques
Survival of Motor Neuron 1 Protein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
153Références
PLoS One. 2017 Feb 21;12(2):e0172346
pubmed: 28222119
N Engl J Med. 2018 Feb 15;378(7):625-635
pubmed: 29443664
Mol Neurobiol. 2018 Aug;55(8):6307-6318
pubmed: 29294245
Pediatr Neurol. 2015 Oct;53(4):293-300
pubmed: 26260993
Genet Med. 2020 Mar;22(3):557-565
pubmed: 31607747
Orphanet J Rare Dis. 2019 Jun 24;14(1):152
pubmed: 31234869
J Neuromuscul Dis. 2020;7(2):109-117
pubmed: 32144995
J Med Econ. 2020 Jan;23(1):70-79
pubmed: 31322019
J Pediatr. 2017 Nov;190:124-129.e1
pubmed: 28711173
Neuromuscul Disord. 2010 Mar;20(3):155-61
pubmed: 20074952
J Neuromuscul Dis. 2018;5(2):145-158
pubmed: 29614695
Mol Genet Metab Rep. 2019 Sep 18;21:100514
pubmed: 31641587
Orphanet J Rare Dis. 2017 Aug 18;12(1):141
pubmed: 28821278
Neuromuscul Disord. 2018 Feb;28(2):103-115
pubmed: 29290580
Mol Genet Genomic Med. 2018 Jan;6(1):99-108
pubmed: 29169204
Annu Rev Genomics Hum Genet. 2020 Aug 31;21:231-261
pubmed: 32004094
J Neuromuscul Dis. 2020;7(2):97-100
pubmed: 32007960
Eur J Hum Genet. 2020 Jan;28(1):23-30
pubmed: 31363188
Neuromuscul Disord. 2019 Nov;29(11):842-856
pubmed: 31704158
Neurology. 2019 Aug 6;93(6):267-269
pubmed: 31235659
Eur J Paediatr Neurol. 2018 Nov;22(6):944-950
pubmed: 30219357
Orphanet J Rare Dis. 2016 May 04;11(1):58
pubmed: 27145956
Lancet. 2017 Dec 17;388(10063):3017-3026
pubmed: 27939059
N Engl J Med. 2017 Nov 2;377(18):1713-1722
pubmed: 29091557
Genet Med. 2018 Jun;20(6):608-613
pubmed: 29758563
Bull World Health Organ. 2008 Apr;86(4):317-9
pubmed: 18438522
PLoS One. 2020 Mar 23;15(3):e0230677
pubmed: 32203538
J Neuromuscul Dis. 2019;6(4):503-515
pubmed: 31594245
J Clin Invest. 2019 Nov 1;129(11):4817-4831
pubmed: 31589162
Nat Biotechnol. 2010 Mar;28(3):271-4
pubmed: 20190738